Core Viewpoint - The stock price of Canar Medical Co., Ltd. closed at 24.22 yuan on August 20, 2025, reflecting a decrease of 0.14 yuan or 0.57% from the previous trading day [1] Company Overview - Canar Medical operates in the medical device sector, focusing on the research, production, and sales of medical products, veterinary products, and laboratory consumables [1] - In the 2024 annual report, medical products accounted for 51.23% of the company's revenue, while veterinary products made up 39.03% [1] Recent Developments - On August 20, 2025, Canar Medical announced that its wholly-owned subsidiary, Jiangsu Canar Medical Technology Co., Ltd., received three utility model patent certificates from the National Intellectual Property Administration. The patents include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe," all of which are related to the company's main business products [1] Financial Performance - On August 20, 2025, the main funds experienced a net outflow of 716,700 yuan, with a cumulative net outflow of 4,222,500 yuan over the past five days [1]

Group 1 - The core point of the article is that Canar Medical Technology Co., Ltd., a wholly-owned subsidiary of Canar Co., has recently received patent certificates from the National Intellectual Property Administration for three medical products [2] - The patents granted include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe" [2] - For the fiscal year 2024, Canar's revenue composition is as follows: medical products account for 51.23%, veterinary products for 39.03%, laboratory consumables for 7.61%, and others for 2.13% [2]